

Supplementary information

1 **Inducible cell-specific mouse models for paired epigenetic and transcriptomic studies of** 2 **microglia and astroglia**

3 **Authors:** Ana J. Chucair-Elliott^{1 §}, Sarah R. Ocañas^{1,2 §}, David R. Stanford¹, Victor A. Ansere^{1,2},
4 Kyla B. Buettner^{1,2}, Hunter Porter^{1,3}, Nicole L. Eliason⁴, Justin J. Reid⁵, Amanda L. Sharpe⁴,
5 Michael B. Stout⁶, Michael J. Beckstead⁵, Benjamin F. Miller⁵, Arlan Richardson^{7,8}, Willard M.
6 Freeman^{1,7,8*}

7 ¹Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City,
8 OK USA, ²Department of Physiology, University of Oklahoma Health Sciences Center,
9 Oklahoma City, OK USA, ³Oklahoma Center for Neuroscience, University of Oklahoma Health
10 Sciences Center, Oklahoma City, OK USA, ⁴Department of Pharmaceutical Sciences, University
11 of Oklahoma Health Sciences Center, Oklahoma City, OK USA, ⁵Aging & Metabolism Program,
12 Oklahoma Medical Research Foundation, Oklahoma City, OK USA, ⁶Department of Nutritional
13 Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK
14 USA, ⁷Department of Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma
15 City, OK, USA, ⁸Oklahoma City Veterans Affairs Medical Center, Oklahoma City, OK USA


16 **To whom correspondence should be addressed:** [^]Willard M. Freeman, Genes & Human
17 Disease Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma
18 City, OK 73104, USA.

19 **Tel:** 405-271-3139

20 **Fax:** 405-271-2536


21 **E-mail address:** bill-freeman@omrf.org

22 [§]*These authors contributed equally*




23 **Supplementary Figure 1. DNA Recombination in brain regions of the Aldh111-NuTRAP**
 24 **model.**


25 Aldh111-cre⁺ NuTRAP⁺ and cre negative NuTRAP⁺ mice were treated with Tam or left untreated
 26 and after a week brains were dissected for immunohistochemistry (IHC) analyses of frozen
 27 sections immunostained with antibodies against mCherry and GFP. Representative confocal
 28 fluorescent microscopy images of sagittal brain sections show colocalization of EGFP (green
 29 signal) and mCherry (red signal) in **(a)** cortex (CTX), **(b)** cerebellum (CB), and **(c)** hippocampus
 30 (HC) of the Aldh111-NuTRAP. Untreated counterparts did not display EGFP or mCherry
 31 expression. Scale bar: 50 μ m.




32 **Supplementary Figure 2. Flow cytometry and immunohistochemical assessment of Tam-**
 33 **independent recombination in the Aldh111-NuTRAP brain.** Aldh111-cre⁺ NuTRAP⁺ and cre
 34 negative NuTRAP⁺ mice were treated with Tam or left untreated and after a week brains were
 35 dissected for flow cytometry (FC) and immunohistochemistry (IHC) analyses. **a** Representative
 36 FC plots of single- cell suspensions show a distinct population of EGFP⁺ cells (25.76%) in brain
 37 samples of Aldh111-NuTRAP mice treated with Tam. Such EGFP⁺ cell population was negligible
 38 (0.05-0.19%) in brains of Aldh111-NuTRAP mice left untreated or cre negative NuTRAP positive
 39 mice treated with Tam (n=2/group). **b-c''** Representative confocal fluorescent microscopy images
 40 of sagittal brain sections captured in the dentate gyrus of the hippocampus show colocalization
 41 of EGFP (green signal) and mCherry (red signal) to GFAP expressing cells (blue signal:
 42 astrocytes) in the Aldh111-NuTRAP. Untreated counterparts did not display EGFP or mCherry
 43 expression. In panel b'-b'' and c'-c'', cells depicted with yellow arrows are shown in the insets (2X
 44 digital zoom) (n=3/group). Scale bar: 50μm.




45 **Supplementary Figure 3: Enrichment distributions.** **a** Distributions of enrichments in gene
 46 expression (Positive fraction/Input) for each of the ribosomal profiling methods against the cell
 47 type marker gene lists developed from cell sorting studies (Supplementary Data 1). **b**
 48 Distributions of enrichments for genes observed as markers (statistically significant, fold change
 49 >5) in only one ribosomal profiling study (Figure 3e) or from the cell sorting studies (Figure 3g).




50 **Supplementary Figure 4. Differential gene expressions in Aldh111-NuTRAP positive**
 51 **fraction strongly correlate with physiological functions of astrocytes in the brain.**
 52 Heatmaps show in the TRAP positive fraction of Aldh111-NuTRAP brains is: (a) enriched in
 53 astrocyte marker genes compared to input, in agreement with over-representation of genes that
 54 are critical in astrocyte physiological functions such as (b) cholesterol synthesis and transport, (c)
 55 fatty acid metabolism, (d) receptors/channels, and (f) synapse modification (formation, function,
 56 and elimination) processes while (e) under-representation of complement/immune mediators,
 57 commonly associated with microglial function.




58 **Supplementary Figure 5. DNA Recombination in brain regions of the Cx3cr1-NuTRAP**
 59 **model.** Cx3cr1-cre⁺ NuTRAP⁺ and cre negative NuTRAP⁺ mice were treated with Tam or left
 60 untreated and after 4 weeks brains were dissected for immunohistochemistry (IHC) analyses of
 61 frozen sections immunostained with antibodies against mCherry and GFP. Representative
 62 confocal fluorescent microscopy images of sagittal brain sections show colocalization of EGFP
 63 (green signal) and mCherry (red signal) in **(a)** cortex (CTX), **(b)** cerebellum (CB), and **(c)**
 64 hippocampus (HC) of the Cx3cr1-NuTRAP. Untreated counterparts did not display EGFP or
 65 mCherry expression, but not specific background (noted especially in CTX). Scale bar: 50 μm.




66 **Supplementary Figure 6. Flow cytometry and immunohistochemical assessment of Tam-**
67 **independent recombination in the Cx3cr1cre-NuTRAP brain.** Cx3cr1-cre/ERT2⁺; NuTRAP⁺
68 and Cx3cr1-cre/ERT2⁻; NuTRAP⁺ mice were treated with Tam or left untreated and after three
69 weeks brains were dissected for flow cytometry (FC) and immunohistochemistry (IHC) purposes.
70 **a** Representative FC plots of single-cell suspensions show a distinct population of EGFP⁺ cells
71 (4.68%) in brain samples of Cx3cr1-cre/ERT2⁺ mice treated with Tam that almost exclusively co-
72 expressed CD11b (96.62%) and was undetectable (0.02 %) in brains of Cx3cr1-cre/ERT2⁻ held
73 to the same treatment. In Cx3cr1-cre/ERT2⁺ mice that did not receive Tam, EGFP⁺ were detected
74 at a lesser level than in treated counterparts (1.17%) (n=2/group). **b-c''** Representative confocal
75 fluorescent microscopy images of sagittal brain sections captured in the hippocampus show
76 colocalization of EGFP (green signal) and mCherry (red signal) to CD11b expressing cells (blue
77 signal) in the Aldh11i-cre/ERT2⁺. Untreated counterparts had almost no EGFP or mCherry
78 expression. In panel b'-b'' and c'-c'', cells depicted with yellow arrows are shown in the insets (2X
79 digital zoom) (n=3/group). Scale bar: 50 μ m.



80 **Supplementary Figure 7. Differential gene expressions in Cx3cr1-NuTRAP positive fraction**
 81 **correlate with enrichment of canonical targets of microglial SPI1 in the brain.** Genes
 82 enriched in the microglia transcriptome included an overrepresentation of genes regulated by
 83 PU.1 (also known as Spi1), a transcription factor that shapes the homeostatic functions of
 84 microglia.




85 **Supplementary Figure 8. Enrichment distributions.** **a** Distributions of enrichments in gene
 86 expression (Positive fraction/Input) for each of the ribosomal profiling methods against the cell
 87 type marker gene lists developed from cell sorting studies (Supplementary Data 2). **b**
 88 Distributions of enrichments for genes observed as markers (statistically significant, fold change
 89 >5) in only one ribosomal profiling study (Figure 6e) or from the cell sorting studies (Figure 7g).




90 **Supplementary Figure 9. Transcriptomic comparison of astrocytes and microglia.** **a**
 91 Positive fractions from Aldh111-NuTRAP and Cx3cr1-NuTRAP were compared. **b** Regulator
 92 analysis comparison. **c** Pathway analysis comparison.


a Aldh111-cre/ERT2; NuTRAP model oxBS Conversion efficiency




b Cx3cr1-cre/ERT2; NuTRAP model oxBS Conversion efficiency




93 **Supplementary Figure 10. Conversion efficiency of CEGX spike-in controls.** Exogenous
94 control sequences (CEGX, Cambridge, UK) with methylation and hydroxymethylation at specific
95 bases were spiked in to each sheared DNA sample (0.04% w/w) prior to oxidation and/or bisulfite
96 conversion. After sequencing, raw fastq files were run through CEGXQC v0.2, a custom FASTQC
97 program, to generate summary documents and QC reports based on the conversion performance
98 of the spike-in sequencing controls. **a-b** Conversion percentages for different cytosine
99 modifications (C, mC, and hmC) are plotted for bisulfite-converted and oxidative bisulfite-
100 converted libraries. Bisulfite-converted libraries show high conversion of unmodified cytosines
101 and low conversion of methylated and hydroxymethylated cytosines. While oxidative bisulfite-
102 converted libraries show high conversion of unmodified cytosines and hydroxymethylated
103 cytosines, and low conversion of methylated cytosines. The bisulfite-converted libraries are used
104 to determine the total percent modified cytosines (mC+hmC), while the oxidative bisulfite-
105 converted libraries are used to determine the percent methylated cytosines (mC).



106 **Supplementary Figure 11. CpG island, shore and shelf methylation and**
 107 **hydroxymethylation in the Aldh111- NuTRAP and Cx3cr1- NuTRAP mouse brains by**
 108 **WGoBS.** After Tam treatment, half brain hemispheres were harvested from Aldh111-NuTRAP
 109 and Cx3cr1-NuTRAP mice and subjected to nuclei isolation and subsequent INTACT protocol for
 110 genomic DNA extraction for epigenome analyses. Analysis of methylation and
 111 hydroxymethylation levels covering CpG islands, shores, and shelves revealed that the shores
 112 and shelves of Cx3cr1-NuTRAP INTACT positive fractions cells had significantly higher mCG
 113 levels **(a-b)** and significantly lower hmCG levels **(c-d)** compared to the other groups. (n=8/input
 114 group, n=4/positive fraction group; 2-way ANOVA with Tukey's multiple comparison test, *p<0.05,
 115 **p<0.01).




116 **Supplementary Figure 12. Comparison of whole genome, repeat, and non-repeat levels of**
 117 **methylation and hydroxymethylation between input and positive fractions of INTACT-**
 118 **isolated DNA from Aldh111-NuTRAP and Cx3cr1-NuTRAP mouse brains. a** Overall repetitive
 119 elements have higher levels of CG methylation and non-repetitive elements have lower levels of
 120 CG methylation than whole genome levels. While there are no differences in total mCG between
 121 the input DNA, Aldh111+ DNA, and Cx3cr1+ DNA in the whole genome or repeat elements, there
 122 is a small, but significant, difference in mCG between Aldh111+ DNA and Cx3cr1+ DNA in non-
 123 repeat elements of the genome. **b** There is less hmCG of Cx3cr1+ DNA than both input DNA and
 124 Aldh111+ DNA at the whole genome level and in repetitive and non-repetitive elements. **c** There
 125 is less mCH of Cx3cr1+ DNA than both input DNA and Aldh111+ DNA at the whole genome level
 126 and in repetitive and non-repetitive elements. **d** LINES contain less mCG in Cx3cr1+ DNA than in
 127 input DNA or Aldh111+ DNA. **e** LINES, SINES, and LTRs have lower hmCG levels in Cx3cr1+ DNA
 128 than in input DNA or Aldh111+ DNA. **f** SINES and LTRs have lower mCH levels in Cx3cr1+ DNA
 129 than input DNA. Simple repeats have lower mCH levels in Cx3cr1+ DNA than in input DNA and
 130 Aldh111+ DNA. Aldh111+ DNA has lower mCH levels in simple repeats than input DNA. (n=8/input
 131 group, n=4/positive fraction group; 2-way ANOVA with Tukey's multiple comparison's test,
 132 *p<0.05, **p<0.01, ***p<0.001).




133 **Supplementary Figure 13. Non-CpG methylation (mCH) in specific gene promoters and**
 134 **intragenic regions in Cx3cr1-NuTRAP and Aldh111-NuTRAP mouse brains by targeted**

135 **BSAS.** DNA from input, Cx3cr1-NuTRAP positive fraction (Cx3cr1-Pos), and Aldh111-NuTRAP
136 positive fraction (Aldh111-Pos) was assayed for region-specific mCH in astrocytic (*Aldh111*, *Fabp7*,
137 *Gfap*, *Kcnj10*) and microglial (*Cx3cr1*, *C1qa*, *Aif1*, *Gpr84*) cell marker genes by targeted BSAS
138 for the same regions as in Figure 10. Average CH methylation (% mCH) at each CH site within
139 the displayed amplicon is plotted. Sites with greater than 1% differences in mCH between at least
140 two groups were analyzed for differential methylation (n=6/group; Two-way ANOVA with Tukey's
141 post-hoc; *p<0.05 Input v. Cx3cr1-Pos, #p<0.05 Input v. Aldh111, ^p<0.05 Cx3cr1-Pos v. Aldh111-
142 Pos). **a-d** For each astrocytic marker gene region assessed (*Aldh111*, *Fabp7*, *Gfap*, *Kcnj10*) there
143 was at least one CH site that was differentially methylated between input, Aldh111-Pos, and/or
144 Cx3cr1-Pos fractions. **e** There were no site-specific differences in mCH within the region of *Cx3cr1*
145 between input, Cx3cr1-Pos, and Aldh111-Pos fractions. **f-h** For each microglial marker gene
146 region assessed (*C1qa*, *Aif1*, *Gpr84*) there was at least one CH site that was differentially
147 methylated between input, Aldh111-Pos, and/or Cx3cr1-Pos fractions.




148 **Supplementary Figure 14. Correlation between gene promoter methylation and expression**
 149 **in Cx3cr1-NuTRAP and Aldh111-NuTRAP brains. a-k** DNA and RNA were isolated from


150 Cx3cr1-NuTRAP brains (input, negative, and positive fractions) for paired targeted BSAS and
151 qPCR. Correlation of average CG methylation (% mCG) with gene expression (normalized RQ)
152 shows strong negative correlations (Pearson's r; Bonferonni correction for multiple comparisons;
153 *p<0.0045) within microglial-specific marker genes (*Cx3cr1*, *C1qa*, *Gpr84*, *Aif1*). **I-v** DNA and
154 RNA were isolated from Aldh1l1-NuTRAP brains (input, negative, and positive fractions) for paired
155 targeted BSAS and qPCR. Correlation of average CG methylation (% mCG) with gene expression
156 (normalized RQ) shows strong negative correlations (Pearson's r; Bonferonni correction for
157 multiple comparisons; *p<0.0045) within astrocyte-specific marker genes (*Aldh1l1*, *Kcnj10*,
158 *Fabp7*, *Gfap*).




159 **Supplementary Figure 15. LPS systemic treatment as experimental demonstration of the**
 160 **Cx3cr1-cre/ERT2 model.** **a** Schematic of the experimental design for epigenetic and
 161 transcriptomic analyses of brain microglia upon LPS challenge. 3-4 weeks after Tam treatment,
 162 Cx3cr1-cre/ERT2⁺; NuTRAP⁺ mice were subjected to a single ip injection with LPS or PBS as
 163 control and 24 h later their brains dissected for protein and IHC purposes. **b** Validation of systemic
 164 LPS treatment. Blood samples were collected at 4 and 24h after LPS injection before euthanasia
 165 and brain harvest. Plasma samples and brain tissue homogenates were used to measure
 166 concentration of inflammatory cytokines IL-6, TNF α , and IFN γ by suspension array. Values are
 167 expressed as average pg analyte/ml \pm SEM in plasma (4h and 24h time points) and average pg
 168 analyte/mg \pm SEM in tissue (24h time point). **c-f'** Representative confocal fluorescent microscopy
 169 images of sagittal brain sections captured in the hippocampus show EGFP expression (green
 170 signal) was found in cells that co-expressed mCherry (red signal) and CD11b (blue signal). **c''-**
 171 **f'''** 2X digital zoom on cells depicted with yellow arrows in (**c'-d'**) and (**f'**) show co-localization of
 172 EGFP and mCherry with CD11b but not with GFAP or NeuN. * $p < 0.05$ between PBS and LPS
 173 treated groups for each analyte by unpaired T test ($n = 4/\text{PBS}$ group and $5/\text{LPS}$ group). Scale bar:
 174 100 μm .




175 **Supplementary Figure 16. qPCR validation of TRAP-RNA in the Cx3cr1-cre/ERT2 model**
 176 **following LPS treatment.** 3-4 weeks after Tam treatment, Cx3cr1-cre/ERT2⁺; NuTRAP⁺ mice
 177 were subjected to a single ip injection with LPS or PBS as control and 24 h later their brains
 178 harvested and one hemisected half used for TRAP isolation of RNA and downstream analyses.
 179 qPCR analysis of microglial genes (*C1qa* and *Itgam*) and candidate genes related to LPS-induced
 180 inflammation (*Tlr4*, *Myd88*, *Il1α*, *Il1β*, and *Tnfα*) demonstrate both enrichment and higher
 181 magnitude changes in the positive fraction as compared to the input. Bar graphs represent
 182 average RQ ± SEM for each gene expression measured. *, *** p<0.05 and p<0.001 respectively
 183 by two-way ANOVA followed by the Sidak's multiple comparison test (n=4 for PBS group and n=5
 184 for LPS group).




185 **Supplementary Figure 17. Targeted bisulfite amplicon sequencing (BSAS) to assess**
 186 **methylation (mCG) of microglial DNA in cell-specific marker gene promoters 24 hours after**
 187 **LPS challenge in Cx3cr1-NuTRAP mouse brain. *Gpr84*, a microglial marker gene, has (a) lower**
 188 **CG promoter methylation, by BSAS, and (b) higher gene expression, by RNA-Seq, in the**
 189 **INTACT-isolated positive fraction than the input, regardless of LPS treatment. *Aif1*, a microglial**
 190 **marker gene, has (c) lower CG promoter methylation, by BSAS, and (d) higher gene expression, by**
 191 **RNA-Seq, in the INTACT-isolated positive fraction than the input, regardless of LPS treatment.**
 192 ***Fabp7*, an astrocyte marker gene, has (e) no difference in promoter CG methylation between**
 193 **input and INTACT-isolated positive fraction, by BSAS, and (f) higher gene expression, by RNA-**
 194 **Seq, in the INTACT-isolated positive fraction than the input, regardless of LPS treatment. (g,h)**
 195 ***Eno2*, a neuronal marker gene, has higher CG promoter methylation by BSAS (g), and no**
 196 **difference in gene expression by RNA-Seq (h), in the INTACT-isolated positive fraction than the**
 197 **input, regardless of LPS treatment. (2-way ANOVA or mixed effects analysis with Holm-Sidak**
 198 **correction for multiple comparisons, main effect * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$).**




199 **Supplementary Figure 18. Stable isotope labeling study in the Cx3cr1-NuTRAP mouse**
 200 **brain.** Microglial proliferation was measured as incorporation of deuterium into purine
 201 deoxyribose. Mice were given an intraperitoneal injection of 99.9% D₂O and subsequently
 202 provided drinking water enriched with 8% D₂O for 30 days. Following INTACT-DNA isolation, DNA
 203 was hydrolyzed for analysis of the pentafluorobenzyl-*N,N*-di(pentafluorobenzyl) derivative of
 204 deoxyribose by GC-MS. Fraction of new DNA was calculated based on the product/precursor
 205 relationship in samples from input and positive INTACT fractions. Bar graphs represent average
 206 DNA fraction new ± SEM, ** p<0.01 by two-tailed unpaired T test comparison (n=3/input and
 207 n=4/positive fraction).




208 **Supplementary Figure 19. Gating strategy for flow cytometry analysis of tamoxifen induced**
 209 **cre recombination in the Aldh111-NuTRAP model.** Representative density plots from flow
 210 cytometry results illustrate steps followed for gating on EGFP⁺ACSA2⁺ cells (astrocytes) from
 211 single-cell suspension of Aldh111-cre/ERT2⁺NuTRAP⁺ brains analyzed. The gating process
 212 described under Methods section is applied to **(a)** unstained, **(b)** isotype control-PE-Vio770, and
 213 **(c)** ACSA-2-PE-Vio770 stained cells from the same brain cell suspension. 1) Cells are gated in
 214 the scatter range and for (2) subsequent selection of single cells (singlets). 3) Using a combination
 215 of filters, singlets are further gated for positive selection of EGFP⁺ cells that are subsequently
 216 selected as ACSA2⁺ (4: astrocytes). Same gating strategy applied to cre negative counterparts is
 217 represented in **(d-e-f)**. Note: Samples in c and f are the same used to show representative data
 218 in Figure 2.



219 **Supplementary Figure 20. Gating strategy for flow cytometry analysis of microglia in the**
 220 **Cx3cr1-NuTRAP model.** Representative density plots from the flow cytometry results illustrate
 221 steps followed for gating on EGFP⁺CD11b⁺ cells (microglia) from single-cell suspension of
 222 Cx3cr1-NuTRAP brains analyzed. The gating process described under Methods section is applied
 223 to (a) unstained, (b) isotype control-APC, and (c) CD11b-APC stained cells from the same brain
 224 cell suspension. 1) Cells are gated in the scatter range for (2) subsequent selection of single cells
 225 (singlets). 3) Using a combination of filters, singlets are further gated for positive selection of
 226 EGFP⁺ cells that are subsequently selected as CD11b⁺ (4: microglia). Same gating strategy
 227 applied to cre negative sample (Aldh11cre/ERT2⁻; NuTRAP⁺) is represented in (d-e-f). Note:
 228 samples in C and F are the same used to show representative data in Figure 5.




229 **Supplementary Figure 21 Gating strategy for flow cytometry analysis of EGFP expression**
 230 **on ACSA-2 positive single cells in the Aldh111-NuTRAP model.** Representative density plots
 231 from the flow cytometry results illustrate steps followed for gating EGFP⁺ cells from ACSA-2⁺
 232 single cells from single-cell suspension of Aldh111-NuTRAP brains analyzed. Gating strategy is
 233 shown for **(a)** unstained, **(b)** isotype control-APC, and **(c)** ACSA-2-APC stained cells from the
 234 same brain cell suspension. 1) Cells are gated in the scatter range for (2) subsequent selection
 235 of single cells (singlets). 3) Using a combination of filters, singlets are further gated for ACSA-2⁺
 236 and EGFP⁺ expression. Same gating strategy applied to cre negative samples (Aldh111cre/ERT2⁺
 237 ; NuTRAP⁺) is represented in **(d-e-f)**.




Supplementary Figure 22. Gating strategy for flow cytometry analysis of EGFP expression on CD11b positive single cells in the Cx3cr1-NuTRAP model. Representative density plots from the flow cytometry results illustrate steps followed for gating EGFP⁺ cells from CD11b⁺ single cells from single-cell suspension of Cx3cr1-NuTRAP brains analyzed. Gating strategy is shown for **(a)** unstained, **(b)** isotype control-APC, and **(c)** CD11b-APC stained cells from the same brain cell suspension. 1) Cells are gated in the scatter range for (2) subsequent selection of single cells (singlets). 3) Using a combination of filters, singlets are further gated for CD11b⁺ and EGFP⁺ expression. Same gating strategy applied to cre negative samples (Aldh11cre/ERT2⁻; NuTRAP⁺) is represented in **(d-e-f)**.

a EGFP expression on ACSA2⁺ singlets



b EGFP expression on CD11b⁺ singlets



238 **Supplementary Figure 23. a Percentage of ACSA-2 positive single cells that are EGFP+**
239 **following the gating strategy in Supplemental Figure 23.** Data is expressed as mean
240 percentage/brain sample \pm SEM (n=3-4/group). **b** Percentage of CD11b positive single cells that
241 are EGFP+ following the gating strategy in Supplemental Figure 22. Data is expressed as mean
242 percentage/brain sample \pm SEM (n=3/group). *p<0.001 by unpaired T test comparison. Note:
243 samples are the same ones used for analysis shown in Figures 2 and 5.

gene/gene ID	Description	Taqman Gene Expression assay ID
<i>Aldh1l1</i>	aldehyde dehydrogenase 1 family, member L1	Mm03048957_m1
<i>Fabp7</i>	fatty acid binding protein 7, brain	Mm00445225_m1
<i>Gfap</i>	glial Fibrillary Acidic Protein	Mm01253033_m1
<i>Elovl2</i>	elongation of very long chain fatty acids-like 2	Mm00517086_m1
<i>Aqp4</i>	aquaporin 4	Mm00802131_m1
<i>Kcnj10</i>	potassium inwardly-rectifying channel, subfamily J, member 10	Mm00445028_m1
<i>Cx3cr1</i>	C-X3-C Motif Chemokine Receptor 1	Mm00438354_m1
<i>C1qa</i>	complement C1q A Chain	Mm00432142_m1
<i>Gpr84</i>	G protein-coupled receptor 84	Mm00518921_m1
<i>Aif1</i>	allograft Inflammatory Factor 1	Mm00479862_g1
<i>Itgam</i>	Integrin Subunit Alpha M	Mm00434455_m1
<i>Eno2</i>	enolase 2	Mm00469062_m1
<i>Kcnb2</i>	potassium voltage gated channel, Shab-related subfamily, member 2	Mm03057813_m1
<i>Syt2</i>	synaptotagmin II	Mm00436864_m1
<i>Syt4</i>	synaptotagmin IV	Mm01157571_m1
<i>Npas4</i>	Neuronal PAS Domain Protein 4	Mm01227866_g1
<i>Mog</i>	myelin oligodendrocyte glycoprotein	Mm01279062_m1
<i>Neu4</i>	sialidase 4	Mm00620597_m1
<i>Opalin</i>	oligodendrocytic myelin paranodal and inner loop protein	Mm00463365_m1
<i>Il1a</i>	interleukin 1 Alpha	Mm00439620_m1
<i>Il1b</i>	interleukin 1 Beta	Mm00434228_m1
<i>Tlr2</i>	toll- like receptor 2	Mm00442346_m1
<i>Tlr4</i>	toll- like receptor 4	Mm00445274_m1
<i>Myd88</i>	myeloid differentiation primary response gene 88	Mm01351743_g1
<i>Tnf</i>	tumor necrosis factor	Mm00443260_g1
<i>Gapdh</i>	Glyceraldehyde-3-Phosphate Dehydrogenase	4352661
<i>Hprt</i>	hypoxanthine guanine phosphoribosyl transferase	Mm01324427_m1

244 **Supplementary Table 1. Taqman gene expression assays used in qPCR analyses of the**
245 **study.** qPCR was performed with gene-specific primer probe fluorogenic exonuclease assays
246 (TaqMan, Life Technologies, Waltham, MA) and the QuantStudio™ 12K Flex Real-Time PCR
247 System (Applied Biosystems). *Hprt* or *Gapdh* were used as an endogenous control.